Bacil Pharma [BACPHAR] vs Gujarat Themis [GUJTHEM] Detailed Stock Comparison

Bacil Pharma Ltd.

BSE
Loading...

Gujarat Themis Biosyn Ltd.

NSE
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Bacil Pharma Ltd. wins in 4 metrics, Gujarat Themis Biosyn Ltd. wins in 12 metrics, with 1 ties. Gujarat Themis Biosyn Ltd. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Bacil Pharma Ltd. Gujarat Themis Biosyn Ltd. Better
P/E Ratio (TTM) 118.00 73.73 Gujarat Themis Biosyn Ltd.
Price-to-Book Ratio 3.09 13.36 Bacil Pharma Ltd.
Debt-to-Equity Ratio 0.00 27.04 Tie
PEG Ratio -0.91 -17.55 Bacil Pharma Ltd.
EV/EBITDA -312.09 52.76 Gujarat Themis Biosyn Ltd.
Profit Margin (TTM) 134.64% 29.99% Bacil Pharma Ltd.
Operating Margin (TTM) -39.22% 40.16% Gujarat Themis Biosyn Ltd.
EBITDA Margin (TTM) N/A 40.16% N/A
Return on Equity 1.59% 19.64% Gujarat Themis Biosyn Ltd.
Return on Assets (TTM) 1.58% 16.19% Gujarat Themis Biosyn Ltd.
Free Cash Flow (TTM) $4.01M $-251.22M Bacil Pharma Ltd.
Dividend Yield N/A 0.17% N/A
1-Year Return 10.61% 15.75% Gujarat Themis Biosyn Ltd.
Price-to-Sales Ratio (TTM) 154.56 22.23 Gujarat Themis Biosyn Ltd.
Enterprise Value $754.34M $36.09B Gujarat Themis Biosyn Ltd.
EV/Revenue Ratio 137.68 22.65 Gujarat Themis Biosyn Ltd.
Gross Profit Margin (TTM) N/A 83.29% N/A
Revenue per Share (TTM) $0 $15 Gujarat Themis Biosyn Ltd.
Earnings per Share (Diluted) $0.50 $4.40 Gujarat Themis Biosyn Ltd.
Beta (Stock Volatility) 0.55 -0.17 Gujarat Themis Biosyn Ltd.

Bacil Pharma Ltd. vs Gujarat Themis Biosyn Ltd. Stock Performance Analysis

Loading Price Chart...

BACPHAR
GUJTHEM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Bacil Pharma Ltd.-9.98%-20.59%-30.97%-19.51%0.92%5.05%
Gujarat Themis Biosyn Ltd.-0.57%-4.89%4.00%38.98%-1.40%-12.59%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Bacil Pharma Ltd.10.61%366.06%494.15%1,158.50%1,113.06%494.15%
Gujarat Themis Biosyn Ltd.15.75%76.92%76.92%76.92%76.92%76.92%

Performance & Financial Health Analysis: Bacil Pharma Ltd. vs Gujarat Themis Biosyn Ltd.

MetricBACPHARGUJTHEM
Market Information
Market Cap i₹804.20M₹35.41B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i5,58079,452
90 Day Avg. Volume i15,293106,446
Last Close₹39.31₹385.10
52 Week Range₹26.69 - ₹61.80₹225.05 - ₹479.00
% from 52W High-36.39%-19.60%
All-Time High₹62.56 (Dec 16, 2024)₹479.00 (Oct 27, 2025)
% from All-Time High-37.16%-19.60%
Growth Metrics
Quarterly Revenue GrowthN/A0.10%
Quarterly Earnings GrowthN/A-0.04%
Financial Health
Profit Margin (TTM) i1.35%0.30%
Operating Margin (TTM) i-0.39%0.40%
Return on Equity (TTM) i0.02%0.20%
Debt to Equity (MRQ) i0.0027.04
Cash & Liquidity
Book Value per Share (MRQ)₹19.09₹24.29
Cash per Share (MRQ)₹1.22₹0.92
Operating Cash Flow (TTM) i₹3.94M₹970.68M
Levered Free Cash Flow (TTM) i₹4.04M₹487.72M
Dividends
Last 12-Month Dividend Yield iN/A0.17%
Last 12-Month Dividend iN/A₹0.67

Valuation & Enterprise Metrics Analysis: Bacil Pharma Ltd. vs Gujarat Themis Biosyn Ltd.

MetricBACPHAR (Apr 24, 2026)GUJTHEM (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i118.0073.73
Forward P/E iN/AN/A
PEG Ratio i-0.91-17.55
Price to Sales (TTM) i154.5622.23
Price to Book (MRQ) i3.0913.36
Market Capitalization
Market Capitalization i₹804.20M₹35.41B
Enterprise Value i₹754.34M₹36.09B
Enterprise Value Metrics
Enterprise to Revenue i137.6822.65
Enterprise to EBITDA i-312.0952.76
Risk & Other Metrics
Beta i0.55-0.17
Book Value per Share (MRQ) i₹19.09₹24.29

Financial Statements Comparison: Bacil Pharma Ltd. vs Gujarat Themis Biosyn Ltd.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricBACPHAR (2025)GUJTHEM (2025)
Revenue/Sales i01.51B
Cost of Goods Sold i0318.78M
COGS % of Revenue i-21.1%
Gross Profit i01.19B
Gross Margin i-78.9%
Research & Development iN/A34.37M
Operating Income (EBIT) i-1.87M642.49M
Operating Margin i-42.6%
EBITDA i-1.29M713.04M
EBITDA Margin i-47.3%
Pre-Tax Income i4.08M655.38M
Pre-Tax Income % of Revenue i-43.5%
Income Tax i34,460167.66M
Income Tax % of Revenue i-11.1%
Net Income (Profit) i4.04M487.72M
Profit Margin i-32.3%

Balance Sheet & Liquidity Metrics

MetricBACPHAR (2025)GUJTHEM (2025)
Cash & Equivalents i28.57M116.94M
Total Current Assets i29.07M519.73M
Total Current Assets % of Revenue i-34.5%
Total Current Liabilities i1.69M205.60M
Total Current Liabilities % of Revenue i-13.6%
Long-Term Debt iN/A296.36M
Long-Term Debt % of Revenue i-19.7%
Total Shareholders Equity i254.31M2.48B
Retained Earnings i114.61M2.37B
Retained Earnings % of Revenue i-157.4%
Property, Plant & Equipment iN/A411.30M

Cash Flow Statement Comparison

MetricBACPHAR (2025)GUJTHEM (2025)
Operating Cash Flow i3.94M970.68M
Operating Cash Flow % of Revenue i-64.4%
Capital Expenditures i0-1.16B
Free Cash Flow i4.01M-251.22M
FCF Margin i--16.7%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricBACPHARGUJTHEM
Shares Short iN/AN/A
Short Ratio iN/AN/A
Short % of Float iN/AN/A
Shares Outstanding i14.35M108.97M
Float Shares i3.93M29.52M
% Held by Insiders i81.03%71.98%
% Held by Institutions i0.00%1.18%
% Held by Public i18.97%26.84%

Dividend Analysis & Yield Comparison: Bacil Pharma Ltd. vs Gujarat Themis Biosyn Ltd.

MetricBACPHARGUJTHEM
Last 12-Month Dividend iN/A₹0.67
Last 12-Month Dividend Yield iN/A0.17%
3-Year Avg Annual Dividend iN/A₹0.22
3-Year Avg Dividend Yield iN/A0.17%
3-Year Total Dividends iN/A₹0.67
Ex-Dividend DateN/ASep 04, 2025